^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Therapeutic Goods Administration
    Excerpt:
    OPDIVO, as monotherapy is indicated for the treatment of locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC) with progression on or after prior chemotherapy. In patients with tumour EGFR or ALK genomic aberrations, OPDIVO should be used after progression on or after targeted therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

    Excerpt:
    ...The patient's tumor must be free of EGFR gene-sensitive mutations (including but...
    Trial ID:
    NCT04023617
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

    Excerpt:
    ...- Patients with activating epidermal growth factor receptor (EGFR) mutations must have received an EGFR tyrosine kinase inhibitor directed therapy prior to platinum therapy...
    Trial ID:
    NCT03121417